Summary
Financial overview
· Net sales amounted to
· Loss for the period was
· Loss per share, before and after dilution, was
· On
Significant events during the period
· In late August it was announced that
· In mid-September new interim data in RRMM patients with extramedullary disease (EMD) from the pivotal Phase 2 HORIZON trial were presented at the
· At the end of September, it was announced that the patient recruitment in the pivotal Phase 2 HORIZON trial had been completed
Financial overview of the group
[][][]
SEK thousand 2019 2018[1)] 2019 2018[1)] 2018[1)]
Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec
Net sales - - - - -
Operating loss -189,597 -94,051 -495,148 -299,104 -410,963
Loss before tax -189,710 -94,051 -495,520 -299,104 -410,965
Loss for the -189,780 -94,051 -495,801 -299,104 -411,112
period
Earnings per -3.53 -2.14 -9.90 -7.03 -9.58
share before and
after dilution
(SEK)
Cash flow from -207,774 -94,265 -473,592 -224,872 -333,727
operating
activities
Cash and cash 1,122,297 488,869 1,122,297 488,869 375,617
equivalents
at the end of the
period
Research & 80% 73% 79% 75% 76%
development
costs/
Operating
expenses %
1) Earlier periods have been adjusted to reflect correction of errors, see note 7.
Conference call for investors, analysts and the media
The Interim Report Q3 2019 and an operational update will be presented by CEO
Phone numbers for participants from:
Financial calendar
Year-end Report 2019:
Interim Report Q1, 2020:
Annual General Meeting
For further information
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 (0)8 615 20 40
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92
This information is information that
About
For more information please visit www.oncopeptides.com.
https://news.cision.com/oncopeptides-ab/r/interim-report-q3-2019,c2967465
https://mb.cision.com/Main/15404/2967465/1146486.pdf
https://mb.cision.com/Public/15404/2967465/bf19bf19cd494445.pdf
(c) 2019 Cision. All rights reserved., source